🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Masatsune Ogura

Juntendo University

ORCID: 0000-0002-7247-1448
MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

N/A
0Author DataRank · unranked

Indexed papers

4in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 4 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 4 papers. Top paper: “HDL, cholesterol efflux, and ABCA1: Free from good and evil dualism”.

HDL, cholesterol efflux, and ABCA1: Free from good and evil dualism

Journal of Pharmacological Sciences(2022)10.1016/j.jphs.2022.07.004
N/A
0.972DataRank · unranked
34 citations

Masatsune Ogura

Homozygous Familial Hypercholesterolemia

Journal of Atherosclerosis and Thrombosis(2021)10.5551/jat.rv17050
N/A
0.708DataRank · unranked
111 citations

Hayato Tada, Masatsune Ogura, Sachiko Okazaki, Koh Ono, Hitoshi Shimano +9 more

Impact of LDLR and PCSK9 pathogenic variants in Japanese heterozygous familial hypercholesterolemia patients

Atherosclerosis(2019)10.1016/j.atherosclerosis.2019.08.004
N/A
0.604DataRank · unranked
55 citations

Naotaka Ohta, Atsushi Takahashi, Hiroaki Masuda, Rieko Isoda, Suguru Yamamoto +6 more

How can cholesterol efflux capacity be used as a risk factor for atherosclerotic cardiovascular disease?

Expert Review of Cardiovascular Therapy(2025)10.1080/14779072.2025.2569403
N/A
0.165DataRank · unranked
2 citations

Masatsune Ogura